The Economic Conundrum for Antibacterial Drugs-Reference-Cited by-同舟云学术

The Economic Conundrum for Antibacterial Drugs

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Shlaes David M.¹

Affiliation:

1. Anti-Infectives Consulting (retired), Stonington, Connecticut, USA

Abstract

While resistance to antibacterial drugs is increasing globally, it is unevenly distributed. The number of cases that are truly difficult to treat remain below the number required to drive an adequate market for needed new therapies. Without a sufficient market, companies pursuing these drugs risk financial failure. Here, I explore, at least briefly, the current situation and the financial risks to companies. I provide potential solutions to the failed market.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02057-19

Reference25 articles.

1. Centers for Disease Control and Prevention. 2019. Antibiotic resistance data. Centers for Disease Control and Prevention Atlanta GA. https://gis.cdc.gov/grasp/PSA/MapView.html.

2. ECDC. 2017. EARS-Net surveillance data, November 2017. European Centre for Disease Prevention and Control, Solna, Sweden. https://www.ecdc.europa.eu/sites/default/files/documents/EARS-Net-report-2017-update-jan-2019.pdf.

3. Daily cost of delay to adequate antibiotic treatment among patients surviving a hospitalization with community-onset Acinetobacter baumannii pneumonia or sepsis

4. Pseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors

5. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Antibacterial Candidates with New Modes of Action;ACS Infectious Diseases;2024-07-17

2. Antibiotics in the clinical pipeline as of December 2022;The Journal of Antibiotics;2023-06-08

3. Metals to combat antimicrobial resistance;Nature Reviews Chemistry;2023-02-08

4. The Production of Antibiotics Must Be Reoriented: Repositioning Old Narrow-Spectrum Antibiotics, Developing New Microbiome-Sparing Antibiotics;Antibiotics;2022-07-08

5. High mortality from carbapenem-resistant Klebsiella pneumoniae bloodstream infection;Microbial Pathogenesis;2022-06